This article was originally published in The Gray Sheet
Executive SummaryInternational marketing agreement calls for Medtronic to distribute Spinal's Bryan Cervical Disc System outside the U.S. Designed to replace the need for intervertebral fusion procedures to treat degenerative disc disease, the device incorporates biomaterials to duplicate the anatomic function of the natural disc. A CE mark was received in September 2000. An undisclosed minority equity investment in privately held Spinal by Medtronic is included in the deal. Spinal expects to begin U.S. trials later this year
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.